Sunitinib S.K. is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.
Sunitinib S.K. is indicated for the treatment of advanced renal cell carcinoma.
Treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pNET) with disease progression.
